Duesbery NS - Search Results

1

Frankel AE, Kuo SR, Dostal D, Watson L, Duesbery NS, Cheng CP, Cheng HJ, Leppla SH. Frankel AE, et al. Among authors: duesbery ns. Front Biosci (Landmark Ed). 2009 Jan 1;14(12):4516-24. doi: 10.2741/3544. Front Biosci (Landmark Ed). 2009. PMID: 19273366 Free PMC article. Review.

2

Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.

Abi-Habib RJ, Singh R, Leppla SH, Greene JJ, Ding Y, Berghuis B, Duesbery NS, Frankel AE. Abi-Habib RJ, et al. Among authors: duesbery ns. Clin Cancer Res. 2006 Dec 15;12(24):7437-43. doi: 10.1158/1078-0432.CCR-06-2019. Clin Cancer Res. 2006. PMID: 17189417

3

Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage.

Kuo SR, Willingham MC, Bour SH, Andreas EA, Park SK, Jackson C, Duesbery NS, Leppla SH, Tang WJ, Frankel AE. Kuo SR, et al. Among authors: duesbery ns. Microb Pathog. 2008 Jun;44(6):467-72. doi: 10.1016/j.micpath.2007.12.001. Epub 2007 Dec 23. Microb Pathog. 2008. PMID: 18222626

4

Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy.

Alfano RW, Leppla SH, Liu S, Bugge TH, Duesbery NS, Frankel AE. Alfano RW, et al. Among authors: duesbery ns. Cell Cycle. 2008 Mar 15;7(6):745-9. doi: 10.4161/cc.7.6.5627. Epub 2008 Jan 18. Cell Cycle. 2008. PMID: 18245947 Review.

5

Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.

Alfano RW, Leppla SH, Liu S, Bugge TH, Herlyn M, Smalley KS, Bromberg-White JL, Duesbery NS, Frankel AE. Alfano RW, et al. Among authors: duesbery ns. Mol Cancer Ther. 2008 May;7(5):1218-26. doi: 10.1158/1535-7163.MCT-08-0024. Mol Cancer Ther. 2008. PMID: 18483309 Free PMC article.

6

Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.

Alfano RW, Leppla SH, Liu S, Bugge TH, Meininger CJ, Lairmore TC, Mulne AF, Davis SH, Duesbery NS, Frankel AE. Alfano RW, et al. Among authors: duesbery ns. Mol Cancer Res. 2009 Apr;7(4):452-61. doi: 10.1158/1541-7786.MCR-08-0451. Mol Cancer Res. 2009. PMID: 19372576 Free PMC article.

7

Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.

Alfano RW, Leppla SH, Liu S, Bugge TH, Ortiz JM, Lairmore TC, Duesbery NS, Mitchell IC, Nwariaku F, Frankel AE. Alfano RW, et al. Among authors: duesbery ns. Mol Cancer Ther. 2010 Jan;9(1):190-201. doi: 10.1158/1535-7163.MCT-09-0694. Epub 2010 Jan 6. Mol Cancer Ther. 2010. PMID: 20053778 Free PMC article.

8

Anthrax fusion protein therapy of cancer.

Frankel AE, Powell BL, Duesbery NS, Vande Woude GF, Leppla SH. Frankel AE, et al. Among authors: duesbery ns. Curr Protein Pept Sci. 2002 Aug;3(4):399-407. doi: 10.2174/1389203023380567. Curr Protein Pept Sci. 2002. PMID: 12370003 Review.

9

Novel protein targeted therapy of metastatic melanoma.

Frankel AE, Koo HM, Leppla SH, Duesbery NS, Vande Woude GF. Frankel AE, et al. Among authors: duesbery ns. Curr Pharm Des. 2003;9(25):2060-6. doi: 10.2174/1381612033454162. Curr Pharm Des. 2003. PMID: 14552326 Review.

10

BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin.

Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, Frankel AE. Abi-Habib RJ, et al. Among authors: duesbery ns. Mol Cancer Ther. 2005 Sep;4(9):1303-10. doi: 10.1158/1535-7163.MCT-05-0145. Mol Cancer Ther. 2005. PMID: 16170021

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54 results

Search Page